Synendos Therapeutics AG’s Post

🌟 Exciting Breakthroughs in Alzheimer's Disease Therapeutics! 🌟 The battle against Alzheimer's is witnessing groundbreaking progress! We're on the brink of transformative treatments, from advanced diagnostic tools to FDA-approved drugs targeting amyloid-beta plaques. Innovative research into tau proteins, neuroinflammation, and the gut-brain axis is opening new therapeutic avenues. Plus, the emphasis on lifestyle interventions highlights the power of preventive measures. This hopeful horizon is a testament to the relentless pursuit of understanding and combating this challenging disease. Let's stay optimistic, and support continued advancements! https://lnkd.in/djTnkjen Pratik Lahiri #AlzheimersResearch #Breakthroughs #Neuroscience #HealthInnovation #EndAlzheimers

Our novel therapeutic approach targets a mechanism of action to promote #neurogenesis and #neuroprotection. Learn more about how dysreglations in this naturally occurring process leads to #neurologicaldisorders. https://lnkd.in/gmaxiKzx

Exciting News! We're thrilled to announce that we've initiated our First-in-Human Clinical Trial for the treatment of neurodevelopmental disorders. In this landmark achievement, we've successfully dosed the first two cohorts of subjects and we are moving forward to the third one in a first-in-human Phase 1 clinical trial of IAMA-6, our promising small molecule designed to target NKCC1. IAMA-6 is our lead clinical program, representing a breakthrough in addressing neurodevelopmental disorders. This highly selective small molecule, designed for oral administration, targets NKCC1-associated neuronal hyperexcitability. Preclinical studies have demonstrated its safety and efficacy, paving the way for its evaluation in a Phase 1 clinical trial. The therapeutic potential of IAMA-6 extends to a spectrum of neurodevelopmental disorders, including epilepsy and other central nervous system disorders, offering hope for patients and families affected by these conditions. Learn more about our mission at https://lnkd.in/d7ayaMWE #IAMAtherapeutics #Neurodevelopment #ClinicalTrial #Neuroscience #Biotech

The Simoa® Human Neurology 4-Plex E (N4PE) assay, now available on the Simoa Advantage Plus® platform, simultaneously measures four biomarkers in EDTA plasma and CSF. Each biomarker (Aβ40, Aβ42, GFAP, NfL) has been demonstrated to have significance for the investigation of neurodegeneration and brain injury and to have utility for monitoring the effectiveness of drug discovery and development for neurological disease. Discover the full applications of N4PE: https://bit.ly/3TovTmt #NeurologyResearch #Biomarkers #SimoaAssay

Accelerating  Drug Discovery in CNS Disorders

Check out our new article on the effects of the ROCK inhibitor #fasudil in the #tau P3O1s model of #alzheimersdisease published in Frontiers in Aging Neuroscience!

Adriana González-Caballero joined her Kx Advisors and BGB Group colleagues reporting on findings from the annual Alzheimer's Association International Conference in Philly as one of our distinguished neurology experts. In partnership with Chris Waybill, Chloe Weiser, and BGB Group colleagues Juan M. Valdez Capuccino, Ph.D. and Exene Anderson, PhD, Adriana is digging a bit deeper into one of the topics that came up - diagnostic hurdles and blood biomarkers in Alzheimer's Disease diagnosis. Did you know the average predicted wait time between clinical diagnosis and treatment of AD is 18.6 months? We invite you to learn more about the different types of BBMs and how they may evolve patient diagnosis of AD and the treatment journey. Read more about this topic in the link below: https://go.bgbx.ai/BBBM

This cohort #study found that the p-tau217 #immunoassay showed similar accuracies to cerebrospinal fluid #biomarkers in identifying abnormal amyloid β (Aβ) and tau pathologies. A 3-range reference for detecting abnormal Aβ pathology was consistent across 3 cohorts; over 8 years, the largest change of p-tau217 was in #individuals positive for both Aβ and tau. Phosphorylated tau (p-tau) is a specific blood #biomarker for #alzheimers disease (#ad ) #pathology , with p-tau217 considered to have the most utility. However, availability of p-tau217 tests for #research and #clinical use has been limited. Expanding #access to this highly accurate AD biomarker is crucial for wider evaluation and #implementation of AD #blood tests. This study found that a commercially available #plasma p-tau217 #immunoassay accurately identified #biological AD, comparable with results using #csf biomarkers, with reproducible cut-offs across cohorts. It detected longitudinal changes, including at the #preclinical stage. https://lnkd.in/eBuF2NS9

Our latest publication in CNS Neuroscience & Therapeutics is out now!! ✨✨✨ you can read our very interesting findings on statins' role in parkinson's disease here https://lnkd.in/ddkbP9TT

【Cited FineTest ELISA Kit】MAP1LC3B ELISA Kit | Alzheimer's Research & Therapy | IF: 9 Abstract: FineTest MAP1LC3B ELISA Kit is cited by an article entitled "PACAP-Sirtuin3 alleviates cognitive impairment through autophagy in Alzheimer's disease" Published in Alzheimer's Research & Therapy. (Read Full Text: https://bit.ly/3QvkpMx) Keywords: #AlzheimersDisease, #AlzheimersResearch, #CognitiveHealth, #CognitiveScience, #MentalHealth, #NeurologicalDisorders, #NeurodegenerativeDiseases, #Neuroscience, #NeuroscienceResearch, #Autophagy